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and activating TNFR2 and Integrin associated chondro-protective
pathways (Fig 3).
Fig 1A. LIPUS enhances chondrogenesis and neutralizes IL-1beta B) LIPUS
restores IL-1beta induced chondrocytes migration inhibition.
Figure 2. A)combine treatment of PGRN and LIPUS show synergistic effects
in chondrocytes anabolism. B) LIPUS þPGRN treatment enhances saffron
O staining and protect against cytokines induce cartilage degradation.
Figure 3. PGRN and LIPUS role in inhibition of inﬂammatory and activation
of chondrogenic pathways.
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Purpose: BST-CarGel® is a chitosan-based medical device used to
treat articular cartilage defects. BST-CarGel® is mixed with thepatient’s whole blood (WB) and then injected into the cartilage
defect. BST-CarGel® /WB is intended to physically stabilize the clot,
which will guide and enhance a marrow-derived repair response.
The use of bone marrow (BM) and bone marrow aspirate concen-
trate (BMAC) (containing pluripotent mesenchymal stem cells) in
the treatment of cartilage defects has recently increased in an
attempt to perform a one-stage cell based treatment. This study
optimized the method to obtain and combine BMAC with BST-
CarGel® to create a cell seeded implant which solidiﬁes in situ and
has similar in vitro properties and advantages to the BST-CarGel®/
WB product.
Methods: Bone marrow was withdrawn from the anterior iliac crest of
4 donors using 6 X 10 mL syringes pre-loaded with 1 mL sodium
heparin (1000 Units). The 60 mL heparinized BM was ﬁltered and
concentrated as per Harvest BMAC®, SmartPrep2® system method-
ology. The BMAC cell pellet was resuspended with plasma to a ﬁnal
volume of 10 mL and analyzed for cellular composition. Upon mixture
with BST-CarGel®, the coagulation was re-activated using Plateltex®-
Act (5 Units batroxobin in 500 uL 10% calcium gluconate). BST-CarGel®/
BMAC clot properties were evaluated using an in vitro model where
0.35 mL clots were generated in glass test tubes incubated at 37C and
tested for clot retraction, clotting time and clot macroscopic appear-
ance. Chitosan distribution among clots and cellular morphology were
further characterized by histology. Cellular viability of clots placed in
chondrogenic culture media were also analyzed using 3D confocal
microscopy.
Results: The average white blood cell concentration factor obtained for
BMAC was 6.9X compared to BM. The use of sodium heparin as an
anticoagulant solution led to the BST-CarGel®/BMAC in vitro properties
being similar to BST-CarGel®/WB mixture as opposed to when ACD-A
anticoagulant was used. BST-CarGel®/BMAC clots revealed a 12.3% clot
retraction with a 5 minutes (min.) clotting time (CT) compared to BST-
CarGel®/WB clots (2.6%; 15min. CT) and WB (51.9%; 15min. CT). A
homogenous distribution of chitosan among all blood components and
normal cellular morphology were observed on histology. Cell viability
was observed within the BST-CarGel®/BMAC implant and until natural
clot degradation.
Conclusions: BST-CarGel® can be combined with BMAC, as per the
methodology described to achieve an implant with similar in vitro
properties as the current marketed product. Cell viability was observed
until natural implant degradation. This combination potentially allows
for a new single stage cell based treatment to repair challenging artic-
ular cartilage defects.
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Purpose: The microfracture procedure is used to stimulate mesen-
chymal stem cells (MSCs) to repair cartilage defects. However, instead
of hyaline cartilage, ﬁbrocartilage is formed. This could be caused by
the inﬂuence of inﬂammatory factors in the knee. The infrapatellar fat
pad (IPFP) contains pro- and anti-inﬂammatory macrophages,
secretes many factors into the joint and its secretion pattern might be
changed by joint pathology or obesity. The goal of this study was to
investigate whether factors produced by the IPFP inﬂuence chon-
drogenesis of bone marrow-derived MSCs, whether this could be
inﬂuenced by joint pathology or obesity and whether macrophages
play a role.
Methods: IPFP obtained during total knee replacement (TKR; 22
donors), anterior cruciate ligament reconstruction (ACL; 6 donors) and
